Ngu Khine Dalia Mudawi Pilar Rivera-Ortega Colm Leonard Nazia Chaudhuri George A Margaritopoulos
10.36141/svdld.v37i2.9276
Sarcoidosis Vasc Diffuse Lung Dis
2020;37(2):231-233.
fibrosis ild ipf nsip progressive uip
CC BY-NC-SA
https://pubmed.ncbi.nlm.nih.gov/33093788/
Lung / diagnostic imaging Lung Diseases, Interstitial / diagnosis Pulmonary Fibrosis / diagnosis Tomography, X-Ray Computed
Lung / diagnostic imaging Lung Diseases, Interstitial / diagnosis Pulmonary Fibrosis / diagnosis Tomography, X-Ray Computed Case Reports Adult Anti-Bacterial Agents / therapeutic use Disease Progression Fatal Outcome Forced Expiratory Volume Humans Immunosuppressive Agents / therapeutic use Lung / drug effects Lung / immunology Lung / physiopathology Lung Diseases, Interstitial / drug therapy Lung Diseases, Interstitial / immunology Lung Diseases, Interstitial / physiopathology Male Middle Aged Phenotype Pulmonary Fibrosis / drug therapy Pulmonary Fibrosis / immunology Pulmonary Fibrosis / physiopathology Severity of Illness Index Time Factors Treatment Failure Vital Capacity Anti-Bacterial Agents Immunosuppressive Agents
PMC7569557
33093788
Rapidly non-ipf progressive fibrosing interstitial lung disease: a phenotype with an ipf-like behavior
2020